Demand for Medical 3D Models Prompts Increased Investment From Materialise

Materialise NV (NASDAQ: MTLS) has benefited from the increasing demand for medical 3D models in the U.S.
According to the press release:

Materialise NV, invests in additional medical production capacity in its US operations. The move strengthens the position of Materialise Mimics^® Innovation Suite as a sophisticated medical backbone solution for healthcare professionals. Materialise’s commitment to continuously improve the Mimics Innovation Suite has led to its increased use in hospitals, and other clinical settings and has driven expansion of Materialise operations in the U.S. market. The expansion further enables a complete range of powerful 3D surgical planning options to support patient-specific treatment, and the capacity to expediently provide anatomical models in the US market.

By providing virtual planning software linked with fully integrated Materialise 3D print services, clinicians and surgeons can use vital supplemental information to simulate or evaluate the best options for patient-specific treatment, and facilitate clear communication with patients, co-workers and/or surgical teams. Materialise HeartPrint, for instance, registered as a class 1 medical device in the US, aids cardiovascular specialists in helping plan patient care and select the necessary tools to treat complex cases such as congenital heart surgery or aortic aneurysm interventions.
Materialise continues to evolve its Mimics Innovation Suite capabilities and has made a new version of software that caters to clinicians with a desire to use 3D printing in their case planning. “As a beta participant for Materialise’s latest medical software innovation, I have witnessed the power of their 25 years ‘of experience in medical 3D printing with this software. Materialise is clearly focused on meeting the evolving needs of clinicians, and in being the software solution for the 3D printing process in hospitals.” stated Frank Rybicki, MD, PhD., a long time Materialise collaborator.

Click here to read the full press release.